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While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms 
tumor (WT) is less clear. This retrospective descriptive study evaluates response and outcome of 
irinotecan treatment for different histological subtypes in relapsed WT. 
 
Procedure 
All participating countries were asked to identify patients with relapsed WT (0-18 years) who 
had been treated with irinotecan. Details on clinical characteristics, histological subtype, 
response, survival and toxicity were collected. A literature review was also performed. 
 
Results 
Sixteen patients were identified (median age 5 years, range 0-17) who had been treated with 
irinotecan, either as a single agent (N=1) or incorporated into multi-agent regimens (N=15). At 
initial diagnosis, the majority had advanced stage disease (stage III/ IV: N=11, stage V: N=1) 
and/or high-risk (HR) histology (HR diffuse anaplasia: N=4, HR blastemal-type: N=5). Among 
14 evaluable patients, one complete response (CR) and two partial responses (PR) were observed 
in patients with initial intermediate-risk (IR) (CR and PR) and blastemal-type histology (PR). 
Two of the patients with CR/PR were still alive at last follow-up, both showing no evidence of 
disease. Among the 11 patients who had stable (N=4) or progressive (N=7) disease, one patient 
was alive after 22 months. Our results are consistent with previously published phase I/II studies 




Some responses to irinotecan-containing regimens were registered in relapsed patients with 
initial IR or blastemal-type histology. Irinotecan may benefit a subset of patients with WT; 







Irinotecan has emerged as a promising agent in various pediatric solid tumors, especially for 3 
patients with relapsed, refractory or high-risk disease. This includes a subset of patients with 4 
relapsed Wilms tumor (WT) who have already received initial treatment with three or more 5 
drugs. For these patients survival rates range unsatisfactory between 10-50%, illustrating the 6 
need to explore novel agents like irinotecan.1-3 7 
Irinotecan is a camptothecin compound which interferes with DNA replication and cell division. 8 
Its mechanism of action is similar to that of topotecan; by binding to the topoisomerase-I-DNA 9 
complex it prevents religation of cleaved DNA strands, ultimately leading to cell death. 4,5 10 
So far, no randomized studies on irinotecan have been performed in relapsed WT and limited 11 
information is available from preclinical and phase I/II studies. In the clinical setting, a 12 
protracted, lower-dose schedule is currently advised with daily administration of irinotecan for 5 13 
consecutive days, with diarrhoea and abdominal pain as main dose-limiting toxicities.4 Anti-14 
tumor activity has been observed when irinotecan is used as a single agent or incorporated into 15 
various chemotherapeutic regimens.6-20 Moreover, irinotecan combined with other 16 
chemotherapeutic agents is currently being studied in upfront treatment for metastatic diffuse 17 
anaplastic WT, a subset of patients with a poor prognosis.20 18 
However, the benefits and harms of irinotecan in relapsed WT are still unclear and more data are 19 
needed to determine which patients may benefit from irinotecan treatment. In this study, we 20 
describe the response to irinotecan, either as a single agent or in combination chemotherapy, in 21 
patients with different histological subtypes of relapsed WT. We discuss these data in the context 22 
of a thorough literature review of all publications that assessed irinotecan for WT patients. 23 
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PATIENTS AND METHODS 24 
 25 
Patients 26 
The national coordinators of the International Society of Pediatric Oncology Renal Tumor Study 27 
Group (SIOP-RTSG) were asked to retrospectively identify children (0-18 years) in their 28 
countries, who had been diagnosed with relapsed WT and treated with irinotecan as part of their 29 
chemotherapeutic regimen. Local physicians reviewed the medical records for clinical 30 
characteristics, histology, stage at diagnosis, first-line treatment, number and type of relapse, 31 
salvage treatment schedule, toxicity, tumor response to irinotecan and outcome. Stage and 32 
histology at diagnosis were defined using SIOP criteria: high-risk (HR) tumors included those 33 
with diffuse anaplasia (DA) or blastemal-type (BT) histology after preoperative chemotherapy. 34 
Intermediate risk (IR) tumors were either stromal, epithelial, focal anaplasia, mixed or regressive 35 
histology.21 36 
 37 
Definitions of response and toxicity 38 
Irinotecan response was defined as the best observed response to irinotecan treatment and 39 
derived from the local centers’ reports. The SIOP classifies response according to RECIST 40 
criteria as complete remission (CR), partial remission (PR), stable disease (SD) or progressive 41 
disease (PD).22 Response was evaluated through imaging studies based on respective volume 42 
change after at least one irinotecan-containing cycle. Toxicity data were retrieved from medical 43 
records and categorized into hematological, gastrointestinal, infection/febrile neutropenia or 44 




Literature search 47 
A complete search of the Pubmed database was performed to identify all reports that describe 48 
pediatric WT patients treated with irinotecan, published until July 2016. Search criteria included 49 




Patient characteristics 54 
Sixteen patients with relapsed WT treated with irinotecan either as a single agent or incorporated 55 
into different chemotherapeutic regimens between October 2004 and October 2015 were 56 
identified. Patient characteristics are depicted in table 1. Median age at relapse was five years 57 
(range 0-17 years), and median time between first tumor diagnosis and relapse was 10 months. 58 
Median follow-up after relapse was 10 months (range 2-26 months). The majority of patients had 59 
advanced-stage disease at diagnosis (stage I/II: N=4, stage III: N=4, stage IV: N=7). One patient 60 
had bilateral disease at diagnosis. Most relapses were metastatic (N=12), three patients presented 61 
with a local relapse and one patient had a combined local and metastatic relapse.  62 
Histology at diagnosis was classified as IR in 7 patients and HR in 9 patients (HR-DA in four 63 
and HR-BT in 5 patients). In 9 cases, first-line treatment had consisted of a four-drug regimen 64 
containing cyclophosphamide/ifosfamide, carboplatin, etoposide and doxorubicin 65 
(CCED/ICED). Six patients had experienced multiple relapses; three patients had undergone 66 





Irinotecan treatment 70 
Most patients received five-day irinotecan cycles, with a median number of 2.5 cycles (range 1-71 
12, number of cycles missing in 2 patients) (table 2). Dosing ranged between 11-50 mg/m2/day 72 
(not reported in two patients). Only one patient received irinotecan as a single agent, while the 73 
others were treated with various irinotecan-containing regimens, including vincristine in 10 74 
patients, temozolomide (with/without vincristine) in 5 patients and bevacizumab in two patients. 75 
For one patient, data on additional chemotherapy were missing.  76 
In some patients, irinotecan was directly included in the relapse treatment, while in others it was 77 
started after alternative chemotherapeutic regimens had failed. Only one patient was recorded to 78 
have received a prior camptothecin (topotecan, patient #12 in table 2). 79 
 80 
Response to irinotecan and survival 81 
Response data were available for 14 patients. One patient reached complete response (CR) to 82 
irinotecan in combination with vincristine, partial response (PR) was demonstrated in two 83 
patients, stable disease (SD) in four patients and progressive disease (PD) in the remaining 7. 84 
Overall, three out of 14 patients were alive at last follow-up, ranging from 12 to 22 months, all 85 
without disease. Among the 11 patients who showed SD or PD, only one patient was alive 86 
without evidence of disease after 22 months. 87 
 88 
Patients with IR-WT 89 
The highest response rate was observed in patients with initial IR-histology (6 evaluable patients 90 
with 1 CR, 1 PR and 2 SD). Noteworthy, the two patients with CR/PR were both treated for their 91 
third relapse after initial stage II-III disease. The patient who reached CR had previously 92 
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received autologous stem cell rescue and was treated with an irinotecan-regimen (irinotecan dose 93 
50mg/m2/day) that contained vincristine. She was alive at last follow-up, showing no evidence of 94 
disease after 12 months. The patient with PR had received prior topotecan and received a similar 95 
dose of irinotecan, however combined with vincristine, temozolomide and bevacuzimab. After 96 
reaching PR, this patient developed PD and died of disease after 11 months. One of the patients 97 
with SD had an inactive rest lesion after local radiation therapy and high dose chemotherapy 98 
with autologous stem cell transplantation, and was alive without disease at last follow-up at 22 99 
months.   100 
 101 
Patients with HR-blastemal type WT 102 
For four patients with HR-blastemal type histology response data were available. One reached 103 
PR after irinotecan, one had SD and the other two patients showed PD. The patient with PR was 104 
treated for a second relapse after initial stage III disease. She received vincristine and 105 
temozolomide in addition to irinotecan (irinotecan dose 50mg/m2/day). After reaching PR, she 106 
underwent surgical resection of residual metastatic lung lesions and was alive showing no 107 
evidence of disease at 21 months. 108 
 109 
Patients with HR-diffuse anaplasia WT 110 
After treatment with irinotecan, only SD (N=1) or PD (N=3) was observed in the 4 patients with 111 







Data on toxicity were available for 10 patients. Hematological toxicity was reported in 5 patients 117 
(grade 3: N=4, grade 2: N=1). One patient had to discontinue irinotecan therapy after two cycles 118 
due to grade 4 febrile neutropenia with ICU admission. Four patients had gastrointestinal toxicity 119 
(grade 2 or 3). No toxicity-related deaths were reported and three patients experienced no 120 
toxicity at all. 121 
 122 
Literature review 123 
A Pubmed search retrieved 14 articles describing the administration of irinotecan to pediatric 124 
patients with WT, including phase I and II (pilot) trials, retrospective chart reviews and case 125 
series, summarized in table 3. No randomized trials were found.  126 
Different irinotecan dosages and schedules of administration were used: irinotecan as a single 127 
agent in 5 studies 7,8,10,11,15, combined with temozolomide in 5 studies 9,14,16,18,19, with vincristine 128 
in 5 studies 14,18-20,24 and other combinations including carboplatin 12, cetuximab 13 or 129 
bevacizumab 18,19.  130 
So far, three other studies have reported complete or partial responses to irinotecan in small 131 
numbers of patients with relapsed or refractory WT 10,16,19. Only one of these studies specified 132 
stage and histology, retrospectively describing four patients with relapse after initial stage II-V 133 
favorable histology WT. Response to irinotecan, combined with vincristine, temozolomide and 134 
bevacuzimab, was observed in all four patients (CR: N=2, PR: N=2).19 135 
A recent abstract by Daw et al., presented at the American Society of Clinical Oncology meeting, 136 
described 14 patients with newly diagnosed metastatic diffuse anaplastic WT, prospectively 137 
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treated with irinotecan and vincristine in a phase II trial.20 In this setting, a partial response was 138 




This multi-center retrospective descriptive study found that irinotecan can induce SD or PR in 143 
some patients with relapsed WT. This indicates that irinotecan may benefit a subset of WT 144 
patients. All responses were observed in patients with IR or HR-BT histology, but not in the four 145 
patients with HR-DA tumors. In addition, SD was observed in four patients (1 HR-DA, 1 HR-BT 146 
and 2 IR). 147 
 148 
Currently, standard approaches for relapsed WT include cyclophosphamide, carboplatin, 149 
etoposide and doxorubicin for most patients, with/without ifosfamide, depending on prior 150 
treatment and initial tumor stage and histology.1 A general principle in the treatment of recurrent 151 
WT is to add agents that have not been used in upfront treatment regimens, with the aim to reach 152 
PR and facilitate complete surgical resection or resolution of lesions after radiotherapy. For 153 
patients with initial HR-DA or HR-BT histology, or patients showing no response to salvage 154 
treatment, alternative therapies such as camptothecins are considered.1,2,25 155 
 156 
Irinotecan has shown variable response rates in the heterogeneous group of studies that describe 157 
its use in pediatric solid tumors, including WT, Ewing sarcoma, neuroblastoma, 158 
rhabdomyosarcoma, osteosarcoma, hepatoblastoma and CNS tumors. These were mainly phase I 159 
and II studies and therefore aimed at dose-finding and toxicity. Since the first study by Furman et 160 
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al. in 1999, reported efficacy of irinotecan as a single agent has ranged from no response to 161 
response rates above 30%.7,10,11,26-30 In our study, the majority of patients received irinotecan in 162 
combination with other chemotherapeutic drugs. Xenograft studies have shown that 163 
camptothecins can synergize with microtubule inhibitors such as vincristine, enhancing anti-164 
tumor activity.31 Clinical studies seem to support the theory that irinotecan is more effective 165 
when combined with other chemotherapeutic drugs like vincristine, temozolomide or 166 
bevacizumab, describing response rates up to 70% when these combinations are used.9,13,17,32-35 167 
 168 
Only three other studies, aside from ours, have described complete or partial responses to 169 
irinotecan in small numbers of patients with relapsed or refractory WT.10,16,19 Noteworthy, none 170 
of these studies were randomized and in some of the studies response may have been due to 171 
other agents that irinotecan was combined with. Moreover, none of these studies have compared 172 
irinotecan response in different histological subtypes of WT.  173 
 174 
The only prospective study evaluating a camptothecin for relapsed WT is a phase II topotecan 175 
trial by Metzger et al., showing a 48% objective response rate (PR in 12/25 patients) to topotecan 176 
in multiply relapsed favorable histology WT and less responses in relapsed anaplastic WT (2/11 177 
PR).36 Similarly, a retrospective report on topotecan by Mavinkurve et al. observed more 178 
responses in patients with IR histology (2/14 CR, 1/14 PR) compared to those with HR histology 179 
(2/16 PR).5 Remarkably, Daw et al. describe a response rate of 79% in DA-WT treated with 180 
irinotecan/vincristine in a window phase trial in newly diagnosed tumors, while in our study with 181 
relapsed patients, stable disease was the best observed response in DA-WT.20 Preclinical studies 182 
have suggested that DA-WT can respond to irinotecan treatment.6 We hypothesize that the lack 183 
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of response in DA-WT patients in our study may be due to a clonal evolution towards more 184 
resistant disease in the relapsed setting, however, the small number of treated patients does not 185 
allow for strong conclusions.  186 
 187 
Irinotecan-related toxicity appears to be acceptable. In our study, grade 2-3 gastrointestinal and 188 
hematological toxicity were the most frequently reported, with only one case of grade 4 189 
infection/febrile neutropenia requiring ICU admission.  This is in line with previously published 190 
phase I and II trials on irinotecan in pediatric patients. In these studies, toxicity was generally 191 
well documented and neutropenia and diarrhoea were consistently reported as the most common 192 
toxicities, in most cases grade 1 or 2, with occasional cases of grade 3-4 toxicity.7-19 193 
Furthermore, cephalosporin prophylaxis has been described to effectively reduce irinotecan-194 
associated diarrhoea in children.37 195 
 196 
In conclusion, this study aimed to collect more data on the efficacy of irinotecan in the setting of 197 
recurrent WT, as we are aware of a progressive wider use of this drug outside controlled clinical 198 
trials or protocols. Our results, as well as the reviewed literature, suggest that irinotecan may 199 
contribute to survival in a subset of WT patients, showing some responses in relapsed patients 200 
with IR an HR-BT histology. Prospective data on irinotecan are warranted, as will be collected in 201 
the upcoming UMBRELLA SIOP-RTSG 2016 protocol in which irinotecan is advised for 202 
relapsed HR-WT patients who have failed treatment with more conventional drugs. Furthermore, 203 
studies on the use of irinotecan in upfront cases, rather than in the relapsed setting, are of interest 204 
since they may show higher response rates.  205 
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